NASDAQ$PRAX
Praxis Precision Medicines I · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Praxis Precision Medicines reported Q4 2025 net loss of $88.9M while advancing multiple CNS filings.
Fourth-quarter net loss was $88.9 million as R&D rose on Cerebrum platform work. The company submitted NDAs for ulixacaltamide and relutrigine and highlighted upcoming readouts for vormatrigine and elsunersen.
- Q4 net loss $88.9M on higher R&D spend.
- Two NDA submissions in early 2026.
- EMERALD DEE readout expected in Q4 2026.
- Pipeline targets multi-billion-dollar CNS revenue potential.
Headline financials
Revenue & EPS history
Praxis · Revenue · Quarterly
$0
Revenue by segment
Praxis · $500K total across 1 segment · Q3 2023
- Collaboration Revenue$500K—100.0%
Forward guidance
The release discusses Praxis Precision Medicines's outlook for upcoming periods, including capital allocation, operating priorities, and market risks, without relying solely on numeric EPS bridges.
Tailwinds
- Praxis Precision Medicines cites operational execution and demand trends supporting the outlook.
- Balance sheet and liquidity actions aim to fund growth and returns.
Headwinds
- GAAP profitability remained under pressure in Q4 2025.
- Macro, pricing, and input-cost volatility could pressure margins.
- Segment mix and one-time items may affect quarter-to-quarter comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2025
-0.3%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-4.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+22.3%
Q2 2022
Best reaction
-40.6%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | -6.4% | -22.2% | |
| Q4 2025 | +0.5% | +4.2% | -9.3% | |
| Q3 2025 | -4.7% | -2.2% | +44.4% | |
| Q1 2025 | +0.2% | -3.5% | +16.3% | |
| Q4 2024 | -40.6% | -41.8% | -40.6% | |
| Q3 2024 | +3.6% | +16.6% | -4.0% | |
| Q2 2024 | -1.1% | +2.0% | +13.3% | |
| Q1 2024 | -5.9% | -6.9% | -15.8% | |
| Q4 2023 | +6.3% | +2.3% | -7.3% | |
| Q3 2023 | +1.4% | -0.6% | +21.6% | |
| Q2 2023 | +10.8% | +17.0% | +43.9% | |
| Q1 2023 | -2.8% | -1.9% | -7.7% | |
| Q4 2022 | -4.2% | -13.0% | -77.0% | |
| Q3 2022 | -12.5% | -11.2% | -13.3% | |
| Q2 2022 | +22.3% | +33.2% | -3.4% | |
| Q1 2022 | +14.0% | +28.1% | -77.7% | |
| Q4 2021 | -1.9% | -4.2% | -22.9% | |
| Q3 2021 | +2.4% | +2.0% | -17.1% | |
| Q2 2020 | +12.7% | +35.9% | +42.8% | |
| Q2 2021 | +12.7% | +35.9% | +42.8% | |
| Q1 2021 | -16.4% | -16.1% | -20.2% | |
| Q4 2020 | -6.8% | -11.5% | -34.0% | |
| Q3 2020 | +2.3% | +18.2% | +54.7% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro